|

New Drug Combination for Mesothelioma Wins FDA Approval

ByAlex Strauss
New Drug Combination for Mesothelioma

The FDA has approved a new drug combination for mesothelioma. It is the first systemic treatment for mesothelioma to win FDA approval in 16 years. 

The combination includes a pair of immunotherapy drugs that complement each other. Both drugs are immune checkpoint inhibitors. They are approved to treat people with inoperable pleural mesothelioma. 

“Today’s approval of nivolumab plus ipilimumab provides a new treatment that has demonstrated an improvement in overall survival for patients with malignant pleural mesothelioma,” says Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence.

New Treatment Options Needed

Pleural mesothelioma is a virulent cancer of the membrane that surrounds the lungs. Asbestos exposure is usually the trigger. Many countries have banned asbestos. In the US, asbestos is heavily regulated. Even so, about 2,500 Americans get mesothelioma every year. 

The new drug combination for mesothelioma marks the first new medication for mesothelioma since 2004. That is when Alimta (pemetrexed) became the first-ever mesothelioma drug. 

Alimta was not a cure but it was a breakthrough. Until it’s approval, mesothelioma patients had no good treatment options. 

Today, most mesothelioma patients get chemotherapy with Alimta. It helps about 40 percent of mesothelioma patients live longer than they otherwise would. Doctors hope the new drug combination for mesothelioma will extend survival for more people. 

Yervoy and Opdivo: The New Drug Combination for Mesothelioma

The newly-approved treatment combines Opdivo (nivolumab) and Yervoy (ipilimumab). Opdivo and Yervoy are both monoclonal antibodies. Yervoy helps activate and proliferate T-cells. Opdivo helps existing T-cells discover the tumor. Together, they slow down mesothelioma tumor growth.

The FDA approved the new drug combination for mesothelioma based on the results of a clinical trial. The trial included 605 patients with unresectable pleural mesothelioma. Patients received infusions of Opdivo every two weeks. Some patients also got Yervoy every six weeks. Others had up to six cycles of chemotherapy.

The patients who got the new drug combination for mesothelioma lived a median of 18 months. The patients who had Opdivo and chemotherapy survived for about 14 months. At one year, almost 70 percent of patients who got the immunotherapy drugs were still alive. Only 58 percent of chemotherapy patients lived that long. 

Treatment May Be Especially Helpful for Non-Epithelioid Mesothelioma

Most mesothelioma patients have the epithelioid subtype. These patients tend to respond best to treatment. But the new drug combination for mesothelioma was especially helpful for patients with a non-epithelioid subtype.  

The trial showed these patients lived a median of just 8 months on chemotherapy. The lead investigator said the new regimen “should be considered as a new standard of care” for patients with non-epithelioid mesothelioma. 

An electronic device called Tumor Treating Fields is the only other approved treatment for mesothelioma. Bristol-Myers-Squibb received FDA approval for the Yervoy/Opdivo combo five months ahead of the goal date.

Sources: 

“FDA Approves Drug Combination for Treating Mesothelioma”, FDA Press Announcement, October 2, 2020

“Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma”, Bristol Myers Squibb, Press Release, August 8, 2020, https://news.bms.com/press-release/corporatefinancial-news/opdivo-nivolumab-plus-yervoy-ipilimumab-demonstrates-durable-s

Fowler, Matthew, “Nivolumab Plus Ipilimumab Improves OS in Malignant Pleural Mesothelioma”, August 10, 2020, Cancer Network, https://www.cancernetwork.com/view/nivolumab-plus-ipilimumab-improves-os-in-malignant-pleural-mesothelioma

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

  • | |

    Value of Mesothelioma Surgery Challenged for Healthy Patients

    ByAlex Strauss

    New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…